• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Gloal economic issues impact on pandemic research, VAX production, prep, etc.

AlaskaDenise

In Memoriam
THe lack of capital will probably impact pandemic issues in many ways. This thread is intended to be a place to gather all the specific cases.

The Icelandic banking Collapse is connected to drug development. See http://www.businessweek.com/globalb...op+news_top+news+index+-+temp_news+++analysis

....the ramifications of Iceland's meltdown extend far beyond the tiny Nordic country. Over the past decade, Icelanders have taken advantage of low interest rates offered by the country's banks to finance rapid expansion beyond the island nation in numerous industries. Hafnarfjordur-based Actavis, for instance, is now one of the world's biggest generic drug companies.

Actavis description (from: http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=10637389 )
Actavis Group hf. engages in the development, manufacture, and sale of generic pharmaceuticals. Its products include Gabapentin, Diltiazem, Oxycodone, Ramipril, Cravit, Pentalong, Lovastatin, Citalopram, Troxevasin, and Quinaretic. Actavis?s products are used in various therapeutic areas, including alimentary tract and metabolism, cardiovascular system, nervous system, genito-urinary and sex hormones, anti-infectives for systemic use, musculo-skeletal system, oncology, respiratory system, dermatologicals, and veterinary. The company produces and sells a variety of medicines in various formulations, including tablets, capsules, injectables, suspensions, suppositories, creams, and ointments. It also sells registration dossiers and active pharmaceutical ingredients. In addition, the company, through its subsidiaries, produces various veterinary pharmaceuticals. It has operations in the United States, Germany, the United Kingdom, the Nordic Countries, Turkey, Bulgaria, the Netherlands, Romania, Russia, Central Europe, and Serbia. The company was founded in 1956 and is headquartered in Hafnarfjordur, Iceland.
 
Back
Top Bottom